Search

Displaying results 4951 - 4960 of 5878 in total
  1. Drug

    Furvina

    go.drugbank.com/drugs/DB16547
    Experimental

    It is used to treat dermatological infections.[A228063]

  2. Drug

    Allovectin-7

    go.drugbank.com/drugs/DB17439
    Investigational

    It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]

  3. Drug

    Pimicotinib

    go.drugbank.com/drugs/DB18972
    Investigational

    It was initially developed by Abbisko Therapeutics Co in collaboration with Merck KGaA. [L53748] Pimicotinib was granted Fast Track Designation in December 2023 by the FDA. [L53753]

  4. Drug

    VIR-5818

    go.drugbank.com/drugs/DB28582
    Investigational

    VIR-5818 is under investigation in clinical trial NCT05356741 (To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants

  5. Drug

    3-amino-5-phenylpentane

    go.drugbank.com/drugs/DB02869
    Experimental

    This compound belongs to the phenylpropylamines.

  6. Drug

    3-Acetylpyridine Adenine Dinucleotide

    go.drugbank.com/drugs/DB03363
    Experimental

    A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.

  7. Drug

    Capric acid

    go.drugbank.com/drugs/DB03600
    Investigational

    This compound belongs to the straight chain fatty acids. These are fatty acids with a straight aliphatic chain.

  8. Drug

    mRNA-3927

    go.drugbank.com/drugs/DB17669
    Investigational

    mRNA-3927 is an investigational mRNA therapy that consists of two mRNAs that encode for the alpha and beta subunits of the mitochondrial enzyme propionyl-CoA carboxylase (PCC) encapsulated within a lipid

  9. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47880] The pathophysiology of this disease is mainly attributed to the deficiency of the CD55 protein, which is the main regulator of the complement cascade.[A261105,A261110,A261115].